[1] Chen JF, Wang F, Huang NX, et al. Oligodendrocytes and myelin: active players in neurodegenerative brains[J]? Dev Neurobiol, 2022, 82(2):160-174.
[2] Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre[J]. Brain, 2013, 136(Pt 9):2697-2706.
[3] Feil S, Valtcheva N, Feil R. Inducible Cre mice[J]. Methods Mol Biol, 2009, 530:343-363.
[4] Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol, 2018, 14(3):133-150.
[5] Depp C, Sun T, Sasmita AO, et al. Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease[J].Nature,2023,618(7964):349-357.
[6] Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to bloo-brain barrier dysfunction predicting cognitive decline[J]. Nature, 2020, 581(7806):71-76.
[7] Denk F, Ramer LM, Erskine EL, et al. Tamoxifen induces cellular stress in the nervous system by inhibiting cholesterol synthesis[J]. Acta Neuropathol Commun, 2015, 3:74.
[8] Chen X, Li J, Chen J, et al. Decision-making impairments in breast cancer patients treated with tamoxifen[J]. Horm Behav, 2014, 66(2):449-456.
[9] Bender CM, Paraska KK, Sereika SM, et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review[J]. J Pain Symptom Manage, 2001, 21(5):407-424.
[10] Tomassy GS, Berger DR, Chen HH, et al. Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex[J]. Science, 2014, 344(6181):319-324.
[11] Dimou L, Simon C, Kirchhoff F, et al. Progeny of Olig2-expressing progenitors in the gray and white matter of the adult mouse cerebral cortex[J]. J Neurosci, 2008, 28(41):10434-10442.
[12] Marques S, Zeisel A, Codeluppi S, et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system[J]. Science, 2016, 352(6291):1326-1329.
[13] Jung B, Arnold TD, Raschperger E, et al. Visualization of vascular mural cells in developing brain using genetically labeled transgenic reporter mice[J]. J Cereb Blood Flow Metab, 2018, 38(3):456-468.
[14] Rivers LE, Young KM, Rizzi M, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice[J]. Nat Neurosci, 2008, 11(12):1392-1401.
[15] Kuhlbrodt K, Herbarth B, Sock E, et al. Sox10, a novel transcriptional modulator in glial cells[J]. J Neurosci, 1998, 18(1):237-250.
[16] Zhang Y, Li B, Cananzi S, et al. A single factor elicits multilineage reprogramming of astrocytes in the adult mouse striatum[J]. Proc Natl Acad Sci U S A, 2022, 119(11):e2107339119.
[17] Alikunju S, Abdul Muneer PM, Zhang Y, et al. The inflammatory footprints of alcohol-induced oxidative damage in neurovascular components[J]. Brain Behav Immun, 2011, 25(Suppl 1):S129-136.
[18] Nikolakopoulou AM, Montagne A, Kisler K, et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss[J]. Nat Neurosci, 2019, 22(7):1089-1098.
[19] Montagne A, Nikolakopoulou AM, Zhao Z, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system[J]. Nat Med, 2018, 24(3):326-337.
[20] Armulik A, Genov G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises[J]. Dev Cell, 2011, 21(2):193-215.
[21] Kr?mer-Albers EM, Werner HB. Mechanisms of axonal support by oligodendrocyte-derived extracellular vesicles[J]. Nat Rev Neurosci, 2023, 24(8):474-486.
[22] Wang LL, Serrano C, Zhong X, et al. Revisiting astrocyte to neuron conversion with lineage tracing in vivo[J]. Cell, 2021, 184(21):5465-5481.e5416.
[23] Salinas Tejedor L, Gudi V, Kucman V, et al. Oligodendroglial markers in the cuprizone model of CNS de- and remyelination[J]. HistolHistopathol, 2015, 30(12):1455-1464.
[24] Jorstad NL, Wilken MS, Grimes WN, et al. Stimulation of functional neuronal regeneration from Müller glia in adult mice[J]. Nature, 2017, 548(7665):103-107.
[25] Hao Z, Xu J, Zhao H, et al. The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation[J]. BMC PharmacolToxicol, 2022, 23(1):33.
[26] Cortes E, Lachowski D, Rice A, et al. Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor[J]. Oncogene, 2019, 38(16):2910-2922.
[27] Yoo JJ, Lim YS, Kim MS, et al. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer[J]. PLoS One, 2020, 15(7):e0236506.
[28] Fang Z, Xu H, Duan J, et al. Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice[J]. Signal Transduct Target Ther, 2023, 8(1):94.
[29] Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials[J]. Lancet, 2003, 361(9354):296-300.
[30] de Medina P, Paillasse MR, Segala G, et al. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands[J]. Proc Natl Acad Sci USA, 2010, 107(30):13520-13525.
|